Initial Dose: Ryanodex is supplied in 250 mg vials and is reconstituted with only 5 mL of sterile water for injection. The initial dose of Ryanodex for MH treatment is usually based on the patient's weight. Specific dosing recommendations may vary slightly depending on the clinical situation, so it's essential to follow the guidance of a qualified healthcare provider.
Rapid Administration: Ryanodex is designed for rapid administration, and warming is not required, which can be advantageous in emergency situations. The rapid reconstitution and administration of Ryanodex allow for quicker achievement of therapeutic blood levels.
Limited Data on Redosing: Unlike the older formulations of dantrolene, there is limited available data on the need for redosing Ryanodex during the treatment of MH. Specific recommendations for redosing with Ryanodex are not as well-established.
Comparative Efficacy: Reports indicate that Ryanodex has efficacy and side effects comparable to the older generic versions of dantrolene when used to treat acute MH. It achieves therapeutic blood levels faster and offers the advantage of a shorter preparation time.
Side Effects: Venous Irritation or Thrombosis. Ryanodex has a high pH, which can sometimes cause irritation or thrombosis (clot formation) at the site of administration. To minimize this risk, healthcare providers often administer Ryanodex through a large vein. Other side effects can include nausea, malaise, lightheadedness, and skeletal muscle weakness.
Considerations for Use: Ryanodex is a suitable choice for treating acute MH, particularly in larger children or adults or in settings with limited personnel, such as freestanding ambulatory surgery centers. Its ease of use, shorter preparation time, and faster effective blood concentrations make it a valuable option in these situations.
Cost and Shelf-Life: It's worth noting that Ryanodex typically comes at a higher cost compared to older generic formulations of dantrolene. Additionally, it has a shorter shelf-life, currently at 33 months versus 36 months for older generic versions of dantrolene.
| Feature | Generic dantrolene | Ryanodex |
|---|---|---|
| Initial dose | 2.5 mg/kg IV, given rapidly | Weight-based; follow the guidance of a qualified healthcare provider |
| Redosing | 2.5 mg/kg as often as needed until ETCO2, muscle rigidity, and heart rate fall | Limited data; specific recommendations not well established |
| Maximum total dose | 10 mg/kg IV; no response at that total should prompt reconsidering the diagnosis | — |
| Preparation | Reconstitution is a practical constraint on immediate administration; extra hands can expedite it | 250 mg vial reconstituted with only 5 mL sterile water; no warming required |
| Therapeutic blood levels | — | Reached faster, with shorter preparation time |
| Local reaction | Venous irritation or thrombosis from its high pH | Same; often given through a large vein to minimize the risk |
| Other side effects | Nausea, malaise, lightheadedness, mild to moderate muscle weakness; respiratory muscle weakness at larger doses, especially in debilitated patients | Nausea, malaise, lightheadedness, skeletal muscle weakness |
| Cost and shelf-life | 36-month shelf-life | Higher cost; 33-month shelf-life |
